Disease Application
Cell to Cure’s stem cell product helps repair and regenerate tissue by signaling to other cells, interacting with the immune system, and supporting natural repair processes.
Clinical Trials Across Multiple Disease Areas
Our clinical programme focuses on diseases with a high involvement of inflammation, tissue ischemia and fibrosis to promote tissue regeneration and function and includes clinical Phase I safety trials and Phase II efficacy trials.
Autism and leaky gut syndrome
Children with autism spectrum disorder have an increased incidence of gastrointestinal complications with symptoms such as abdominal pain and obstipation. In leaky gut syndrome, gaps in the intestinal walls allow translocation of bacterial products and toxins into the blood stream. This leakage induces local and systemic inflammation.
It is hypothesised that these circulating toxins and inflammatory factors influence the behavior and well-being of the children.
Cell to Cure conducts dose titrating clinical trials in children with autism and leaky gut syndrome age 6 – 18 years to test safety and improve the gastrointestinal symptoms and thus the behaviour of these children.
Diabetic foot ulcers
One of the most severe complications of diabetes is foot ulcers which annually affect up to 26 million persons with diabetes. Lower limb amputation is a feared complication associated with diabetic foot ulcers, and globally, one person is amputated every 30 seconds due to diabetes. There is currently no effective cure for this indication.
Cell to Cure investigates the safety and efficacy of the treatment of diabetic foot ulcers with injections of stromal cells into the skin around the ulcer in addition to the conventional treatments for improving healing and complications to foot ulcers.
Cardiovascular diseases
Dilated non-ischemic heart failure is a serious condition with a high morbidity and mortality (40-50 % within 5 years). The prevalence of the disease is estimated to be 1 of 250-500 persons and dilated non-ischemic heart failure is the most frequent cause of heart transplantation.
The condition presents a high degree of inflammatory and immunological activity. Cell to Cure conducts clinical trials in patients with dilated non-ischemic heart failure, where our stem cell product can potentially modify this activity and hereby improve the cardiac function.
Eye diseases
With more than 180,000 procedures annually, corneal transplantation/keratoplasty is the most frequent transplantation procedure of human tissue, but the 5-year prognosis for corneal transplant survival is estimated to be as low as 50%.
Ocular graft versus host disease are the most common complications of hematopoietic stem cell transplantation inducing pain, irritation and impaired vision. Cell to Cure joins the Restore Vision project in collaboration with international partners, to investigate whether our cell products can improve these two serious complications.
Want to know more about how our cell product can help you?
